Crystal structure of Mcl1 with inhibitor 7

Experimental Data Snapshot

  • Resolution: 1.70 Å
  • R-Value Free: 0.290 
  • R-Value Work: 0.280 
  • R-Value Observed: 0.280 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.1 of the entry. See complete history


AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel, S.Brown, S.P.Belmontes, B.Moody, G.Keegan, K.S.Chui, D.Whittington, D.A.Huang, X.Poppe, L.Cheng, A.C.Cardozo, M.Houze, J.Li, Y.Lucas, B.Paras, N.A.Wang, X.Taygerly, J.P.Vimolratana, M.Zancanella, M.Zhu, L.Cajulis, E.Osgood, T.Sun, J.Damon, L.Egan, R.K.Greninger, P.McClanaghan, J.D.Gong, J.Moujalled, D.Pomilio, G.Beltran, P.Benes, C.H.Roberts, A.W.Huang, D.C.Wei, A.Canon, J.Coxon, A.Hughes, P.E.

(2018) Cancer Discov 8: 1582-1597

  • DOI: https://doi.org/10.1158/2159-8290.CD-18-0387
  • Primary Citation of Related Structures:  
    6O6F, 6O6G, 6OQB, 6OQC, 6OQD, 6OQN, 6OVC

  • PubMed Abstract: 

    The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer. To overcome the significant challenges associated with inhibition of MCL1 protein-protein interactions, we rigorously applied small-molecule conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans. We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematologic cancer cell lines, tumor xenograft models, and primary patient samples. With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by reductions in B cells, monocytes, and neutrophils. Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses. These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics. SIGNIFICANCE: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies. The synergistic combination of AMG 176 and venetoclax demonstrates robust activity in models of AML at tolerated doses, highlighting the promise of BH3-mimetic combinations in hematologic cancers. See related commentary by Leber et al., p. 1511 . This article is highlighted in the In This Issue feature, p. 1494 .

  • Organizational Affiliation

    Oncology Research, Amgen Inc., Thousand Oaks, California.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Induced myeloid leukemia cell differentiation protein Mcl-1
A, B
157Homo sapiensMutation(s): 0 
Gene Names: MCL1BCL2L3
UniProt & NIH Common Fund Data Resources
Find proteins for Q07820 (Homo sapiens)
Explore Q07820 
Go to UniProtKB:  Q07820
PHAROS:  Q07820
GTEx:  ENSG00000143384 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ07820
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
N0P (Subject of Investigation/LOI)
Query on N0P

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
C26 H31 Cl N2 O5 S
Binding Affinity Annotations 
IDSourceBinding Affinity
N0P Binding MOAD:  6OQN IC50: 10 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.70 Å
  • R-Value Free: 0.290 
  • R-Value Work: 0.280 
  • R-Value Observed: 0.280 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 43.549α = 90
b = 83.953β = 90
c = 89.168γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2019-05-15 
  • Deposition Author(s): Huang, X.

Revision History  (Full details and data files)

  • Version 1.0: 2019-05-15
    Type: Initial release
  • Version 1.1: 2024-03-13
    Changes: Advisory, Data collection, Database references